Compare Charles River Laboratories Intl. Inc (CRL) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs VanEck Rare Earth/Strategic Metals — how do they compare? Charles River Laboratories Intl. Inc trades at $229.77 (market cap $11.14B), while VanEck Rare Earth/Strategic Metals trades at $76.78. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.
| CRL | REMX | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Sector/Thematic |
52-Week High | $233.60 | $109.53 |
52-Week Low | $145.57 | $47.36 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $76.27, down 4.38% today amid bearish technical signals. The ETF faces high volatility (~50% annualized) and significant China concentration risk, though recent news highlights growing institutional interest in rare earths as critical for AI and defense infrastructure. Technical indicators show oversold RSI readings but dominant bearish moving average signals.
Outlook remains speculative given geopolitical supply chain dependencies and commodity price sensitivity. Investment appeal hinges on long-term rare earth demand growth from technology and energy transitions, but risks include China export controls and ETF liquidity constraints. Current levels near support at $76 may attract tactical buyers despite near-term bearish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
